Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
794
Recruiting, any sponsor type, condition "Hodgkin lymphoma"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting794
- Completed2,605
794 trials
Showing 1 to 25, recently updated first.
Arvinas Inc.Industry
NCT06393738 · 329 participants (planned) · Start Sep 5, 2024 · Primary completion Dec 2028
Drug: ARV-393; Glofitamab · For: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Sites: New Haven, Connecticut; Miami, Florida; Detroit, Michigan · 28 sites in all
Fred Hutchinson Cancer CenterAcademic, hospital or other
NCT04195633 · 60 participants (planned) · Start Jan 25, 2021 · Primary completion Apr 15, 2027
Drug: Cyclophosphamide; Cyclosporine and 5 more · For: Acute Leukemia; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia and 16 more
Sites: Seattle, Washington
Cellogen Therapeutics Pvt. Ltd.Industry
NCT07948733 · 18 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 14, 2028
Drug: Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg; Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg and 1 more · For: B-Cell Non-Hodgkin Lymphoma (NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Vellore, India
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05890352 · 227 participants (planned) · Start Sep 26, 2023 · Primary completion Dec 1, 2029
Drug: Lenalidomide; Tafasitamab and 2 more · For: Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements and 3 more
Sites: Tucson, Arizona; Beverly Hills, California; Duarte, California · 104 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02877303 · 80 participants (planned) · Start Nov 1, 2016 · Primary completion Nov 1, 2028
Drug: Blinatumomab; Cyclophosphamide and 10 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma
Sites: Houston, Texas
University of WashingtonAcademic, hospital or other
NCT06784726 · 27 participants (planned) · Start Sep 4, 2025 · Primary completion Apr 10, 2028
Drug: Odronextamab; Chimeric Antigen Receptor T-Cell Therapy · For: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma and 9 more
Sites: Seattle, Washington
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05296304 · 20 participants (planned) · Start Mar 16, 2022 · Primary completion Mar 2027
Drug: Bexarotene · For: Cutaneous T-cell Lymphoma
Sites: Commack, New York; New York, New York; Rockville Centre, New York
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruiting
National Cancer Institute (NCI)NIH
NCT05272384 · 32 participants (planned) · Start Nov 3, 2022 · Primary completion Jun 28, 2027
Drug: Decitabine and Cedazuridine; Nivolumab · For: Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Hodgkin Lymphoma and 3 more
Sites: Birmingham, Alabama; Duarte, California; Sacramento, California · 9 sites in all
University of MiamiAcademic, hospital or other
NCT07002216 · 48 participants (planned) · Start Jul 15, 2025 · Primary completion Jul 15, 2030
Drug: Brentuximab Vedotin; Etoposide and 4 more · For: Hodgkin Lymphoma; Advanced Hodgkin Lymphoma
Sites: Miami, Florida
National Cancer Institute (NCI)NIH
NCT03739814 · 84 participants (planned) · Start May 8, 2019 · Primary completion Feb 1, 2027
Drug: Blinatumomab; Inotuzumab Ozogamicin and 1 more · For: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Anchorage, Alaska; Kingman, Arizona · 285 sites in all
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT07892027 · 26 participants (planned) · Start Nov 10, 2026 · Primary completion May 1, 2028
Drug: Axicabtagene Ciloleucel; Brexucabtagene Autoleucel and 3 more · For: Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma and 1 more
Sites: Ann Arbor, Michigan
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06317662 · 153 participants (planned) · Start Jun 5, 2025 · Primary completion Dec 31, 2028
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 17 more · For: Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 117 sites in all
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT07724457 · 271 participants (planned) · Start Jul 27, 2027 · Primary completion Nov 1, 2033
Drug: Carboplatin; Cyclophosphamide and 11 more · For: Recurrent Burkitt Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory Burkitt Lymphoma and 1 more
Sites: Chicago, Illinois
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04728893 · 490 participants (planned) · Start Apr 5, 2021 · Primary completion Jan 4, 2029
Drug: Nemtabrutinib · For: Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma and 1 more
Sites: Springdale, Arkansas; La Jolla, California; Torrance, California · 121 sites in all
- SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)Pivotal-lookingRecruiting
Nuvation Bio Inc.Industry
NCT05303519 · 365 participants (planned) · Start Jun 5, 2023 · Primary completion Dec 1, 2028
Drug: safusidenib; Placebo · For: Glioma; Astrocytoma, Grade IV; IDH1-mutant Glioma and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 75 sites in all
Incyte CorporationIncyte (INCY)
NCT07853040 · 24 participants (planned) · Start Oct 27, 2026 · Primary completion Mar 31, 2027
Drug: INCB161734 · For: Hepatic Insufficiency; Liver Diseases
Sites: Chandler, Arizona; Orlando, Florida; San Antonio, Texas
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT07478848 · 14 participants (planned) · Start May 29, 2026 · Primary completion Jan 1, 2029
Drug: Vancomycin 125mg; CAR-T · For: Large B Cell Lymphoma; Non Hodgkin Lymphoma (NHL); Diffuse Large B Cell Lymphoma (DLBCL) and 2 more
Sites: Philadelphia, Pennsylvania; Salt Lake City, Utah
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05529069 · 30 participants (planned) · Start Jan 25, 2023 · Primary completion Apr 28, 2027
Drug: Pirtobrutinib; Venetoclax · For: Mantle Cell Lymphoma; Non Hodgkin Lymphoma; Hematologic Malignancy
Sites: Houston, Texas
AIDS Malignancy ConsortiumResearch network
NCT07662928 · 43 participants (planned) · Start Sep 16, 2026 · Primary completion May 30, 2031
Drug: Cyclophosphamide; Doxorubicin and 5 more · For: Adult Burkitt Lymphoma
Sites: New York, New York
Debiopharm International SAIndustry
NCT05765812 · 116 participants (planned) · Start May 15, 2023 · Primary completion Sep 2028
Drug: Zedoresertib; Temozolomide · For: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype; Astrocytoma, Grade III
Sites: Chicago, Illinois; New York, New York; Dallas, Texas · 16 sites in all
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruiting
National Cancer Institute (NCI)NIH
NCT04002947 · 132 participants (planned) · Start Aug 5, 2019 · Primary completion Oct 12, 2027
Drug: DA-EPOCH; Rituximab and 2 more · For: Non-Hodgkin's Lymphoma; Diffuse Large B-Cell Lymphoma; DLBCL and 1 more
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT03258567 · 40 participants (planned) · Start Apr 26, 2018 · Primary completion Jun 1, 2029
Drug: Nivolumab · For: Epstein-Barr Virus Infections; Lymphoma; Lymphoproliferative Disorder and 1 more
Sites: Bethesda, Maryland
Nurix Therapeutics, Inc.Industry
NCT07520006 · 150 participants (planned) · Start Sep 30, 2026 · Primary completion May 2033
Drug: NX-5948; venetoclax and 2 more · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Irvine, California; Aurora, Colorado; Coral Gables, Florida · 10 sites in all
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06806033 · 130 participants (planned) · Start Mar 5, 2025 · Primary completion Jul 31, 2029
Drug: Obinutuzumab; Glofitamab and 2 more · For: Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Sites: Anchorage, Alaska; Clovis, California; Fullerton, California · 53 sites in all
- Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial ChemotherapyPivotal-lookingRecruiting
Eastern Cooperative Oncology GroupResearch network
NCT06724237 · 294 participants (planned) · Start Jun 18, 2025 · Primary completion Apr 30, 2074
Drug: High Dose Chemotherapy; Stem Cell Mobilization Therapy · For: Anaplastic Large Cell Lymphoma, ALK-Negative; Follicular Helper T-Cell Lymphoma; Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type and 1 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 165 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.